ASCENDIS PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 142.1 USD | +1.38% |
|
-2.16% | +12.82% |
Presenter SpeechVikram Purohit (Analysts)Welcome. Let's go ahead and get started. This is the ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
133.5
EUR
Average target price
166.7
EUR
Spread / Average Target
+24.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.82% | 8.12B | |
| +2.49% | 96.73B | |
| -0.20% | 21.31B | |
| -16.61% | 21.21B | |
| -5.24% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 01
